Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/49725
Title: Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: Analysis of data from five randomized, controlled trials
Authors: Raccah, Denis
Lin, Jay
Wang, Edward
Germé, Maeva
Perfetti, Riccardo
Bonadonna, Riccardo C.
De Pablos-Velasco, Pedro 
Roussel, Ronan
Rosenstock, Julio
Keywords: European-Association
Glycemic Control
Therapy
Management
Hyperglycemia, et al
Issue Date: 2014
Publisher: 1056-8727
Journal: Journal of Diabetes and its Complications 
Abstract: Aims: To compare the efficacy and safety of lixisenatide (LIXI), a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist, as add-on to basal insulin (Basal + LIXI) versus once-daily rapid-acting insulin (Basal + RAI) in patients with type 2 diabetes mellitus (T2DM).Methods: Data were extracted from five randomized controlled trials assessing the efficacy and safety of basal insulin + insulin glulisine (n = 3) or basal insulin + LIXI (n = 2). Patients in the Basal + LIXI cohort were matched to patients in the Basal + RAI cohort using propensity score matching.Results: In the matched population, Basal + LIXI was twice as likely to reach composite outcomes of glycated haemoglobin (HbA(1c)) <7% and no symptomatic hypoglycaemia compared with the Basal + RAI group (odds ratio [OR]: 1.90; 95% confidence interval [CI]: 1.01, 3.55; P = 0.0455), as well as HbA(1c) <7% and no severe hypoglycaemia (OR: 1.97; 95 CI: 1.06, 3.66; P = 0.0311). Furthermore, Basal + LIXI was more than twice as likely to reach HbA(1c) <7%, no weight gain and no symptomatic hypoglycaemia (OR: 2.58; 95% CI: 1.23, 5.40; P = 0.0119).Conclusions: Both basal + LIXI and Basal + RAI improved glycaemic control in patients with T2DM with inadequate glycaemic control on basal insulin. Basal + LIXI offers an effective therapeutic option to advance basal insulin therapy, improving glucose control without weight gain and with less risk of hypoglycaemia than prandial insulin. (C) 2014 Published by Elsevier Inc.
URI: http://hdl.handle.net/10553/49725
ISSN: 1056-8727
DOI: 10.1016/j.jdiacomp.2013.10.003
Source: Journal of Diabetes and its Complications[ISSN 1056-8727],v. 28, p. 40-44
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

34
checked on Jul 25, 2021

WEB OF SCIENCETM
Citations

29
checked on Jul 25, 2021

Page view(s)

8
checked on Jul 24, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.